This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| triple-negative breast cancer | |
|---|---|
| Name | Triple-negative breast cancer |
| Field | Oncology |
| Synonyms | TNBC |
triple-negative breast cancer
Triple-negative breast cancer is an aggressive subtype of breast carcinoma characterized by absence of estrogen receptor, progesterone receptor, and HER2 receptor expression. It disproportionately affects younger women and certain populations and is associated with distinct clinical behavior, therapeutic challenges, and active research efforts worldwide.
Triple-negative breast cancer is defined by immunohistochemical and in situ hybridization criteria applied to tumor specimens from patients evaluated at centers such as Mayo Clinic, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, MD Anderson Cancer Center, and Cleveland Clinic. Epidemiologic studies by groups at Centers for Disease Control and Prevention and World Health Organization document higher incidence among African American women, women of Caribbean descent, and carriers of germline mutations reported in cohorts studied by The Cancer Genome Atlas and projects led by Wellcome Trust. Major population surveys reported by National Cancer Institute and registries like Surveillance, Epidemiology, and End Results Program help delineate age, race, and geographic patterns in countries represented by institutions such as University of Oxford, Harvard University, University of California, San Francisco, Karolinska Institutet, and University of Melbourne.
Histologically, many cases show high-grade invasive ductal carcinoma features evaluated by pathologists at Royal College of Pathologists, American Society of Clinical Oncology, and laboratories affiliated with Fred Hutchinson Cancer Research Center. Molecular profiling by The Cancer Genome Atlas and teams at Broad Institute revealed frequent TP53 mutations, BRCA1 pathway deficiencies observed by investigators at Baylor College of Medicine and University of Toronto, and basal-like gene expression signatures described by researchers at European Molecular Biology Laboratory and Dana-Farber Cancer Institute. Studies integrating work from Cold Spring Harbor Laboratory, Sanger Institute, and Institut Curie identify genomic instability, homologous recombination deficiency, and immune-related transcriptional programs similar to patterns analyzed by Memorial Sloan Kettering Cancer Center investigators.
Patients often present with a palpable mass initially assessed in clinics at Guy's and St Thomas' NHS Foundation Trust, Royal Marsden Hospital, Karolinska University Hospital, St Bartholomew's Hospital, or community centers tied to programs like Susan G. Komen Foundation. Diagnostic pathways include imaging with mammography and ultrasound guidelines from American College of Radiology and core needle biopsy protocols standardized by College of American Pathologists; multidisciplinary tumor boards at centers such as Mayo Clinic and Hospital for Special Surgery integrate pathology, radiology, and genetics. Genetic counseling and BRCA testing offered by clinics affiliated with Myriad Genetics and Invitae inform management decisions influenced by analyses from National Comprehensive Cancer Network panels.
Staging follows systems promulgated by American Joint Committee on Cancer and prognostic models refined using data from Surveillance, Epidemiology, and End Results Program, European Organisation for Research and Treatment of Cancer, and collaborative groups like Breast International Group. Prognosis is affected by tumor size, nodal status, and molecular features reported in large series from MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and population cohorts tracked by National Cancer Institute. High early recurrence rates and mortality disparities have prompted policy discussions involving World Health Organization and advocacy by American Cancer Society and Susan G. Komen Foundation.
Management strategies combine surgery performed by teams at institutions including Royal Marsden Hospital and MD Anderson Cancer Center, systemic therapy protocols developed by cooperative groups such as American Society of Clinical Oncology and European Society for Medical Oncology, and radiation techniques refined at Department of Radiation Oncology, Massachusetts General Hospital. Neoadjuvant and adjuvant chemotherapy regimens influenced by trials organized by National Cancer Institute and Cancer Research UK often use agents referenced in guidelines from National Comprehensive Cancer Network; platinum agents and PARP inhibitors studied in trials by AstraZeneca, Pfizer, Merck, and academic consortia are options for BRCA-associated cases. Immunotherapies tested in studies led by teams at Johns Hopkins Hospital, Dana-Farber Cancer Institute, and pharmaceutical collaborations with Bristol Myers Squibb and Genentech have expanded options for selected patients.
Ongoing research at centers like Broad Institute, Sanger Institute, Cold Spring Harbor Laboratory, Institut Curie, and Fred Hutchinson Cancer Research Center explores biomarkers such as PD-L1, tumor-infiltrating lymphocytes characterized by teams at Memorial Sloan Kettering Cancer Center, circulating tumor DNA monitored by laboratories at Stanford University School of Medicine, and homologous recombination deficiency assays developed by companies including Myriad Genetics. Large consortia including The Cancer Genome Atlas and international trials run by groups like Breast International Group and Alliance for Clinical Trials in Oncology investigate targeted agents, antibody–drug conjugates evaluated by Seagen and ImmunoGen, and vaccine strategies with contributions from National Institutes of Health investigators.
Survivorship programs offered by American Cancer Society, support networks coordinated by Susan G. Komen Foundation, psycho-oncology services at Mayo Clinic and Memorial Sloan Kettering Cancer Center, and genetic counseling resources at Myriad Genetics and academic centers address long-term follow-up, fertility preservation collaborations with American Society for Reproductive Medicine, and quality-of-life interventions informed by research from University College London and University of Toronto. Advocacy and policy engagement involve organizations such as Livestrong Foundation and international patient groups that work with healthcare systems represented by National Health Service and agencies including Centers for Disease Control and Prevention.